ACELYRIN, INC.

#HidradenitisSuppurativa (HS) is a chronic skin condition that is often misdiagnosed, leaving patients both constantly uncomfortable and confused on where to turn. Brindley Brooks, HS advocate and founder of HS Connect, has created a network for those with this condition to provide resources and support. Listen below as Brindley shares more about HS Connect's work and learn more about ACELYRIN's research in HS here. https://lnkd.in/e3CGamEw

July is #GravesDiseaseAwarenessMonth. Thyroid Eye Disease (TED) is a prevalent comorbidity of Graves' Disease and can significantly impact a patient’s quality of life due to visual impairment and pain. The Endocrine Society shares insight into why individuals with #GravesDisease are prone to developing TED here. https://lnkd.in/gSy3gKJw

We are proud to foster a vibrant and inclusive workplace at ACELYRIN. In our final #Pride2024 spotlight, Chief Technical Operations Officer Patricia Turney shares what Pride means to her as a member of the LGBTQIA+ community. Patricia is instrumental in championing employee engagement, well-being, and collaboration through her work with the ACELYRIN Culture & Engagement (ACE) group.

Pride Month serves as an opportunity to emphasize acceptance, equality and the work of the LGBTQIA+ community and its impact on history. Our South San Francisco office facilities supervisor Jasmine Garcia shares what #Pride2024 means to her below.

We are pleased to announce that Philip Mease, M.D. of Providence Swedish Medical Center will present positive results from our global Phase 2b/3 clinical trial of izokibep in #psoriaticarthritis (PsA) at #EULAR2024 this weekend in Vienna. Read more about the presentation here: https://lnkd.in/ejKza6xq

The unknown aspects of participating in clinical trials can be daunting for any patient, especially those with lesser-known conditions like #HidradenitisSuppurativa (HS). HS is a debilitating, chronic, and complex inflammatory illness, often described as an immune-mediated inflammatory disease or follicular occlusion disorder. This #HSAwarenessWeek, HS advocate and founder of HS Connect Brindley Brooks speaks to the importance of transparency in clinical trial processes.

At ACELYRIN, we take #pride in our team's unique backgrounds and perspectives. We are excited to kick off #PrideMonth with Senior Manager, Clinical Operations, Samyuktha Manne. Samy shares why she takes pride in being an ally and celebrating the LGBTQIA+ community. Listen in below. 🏳️🌈

ACELYRIN Chief Executive Officer, Mina Kim, will participate in a fireside chat at #JefferiesHealthcare tomorrow. She looks forward to sharing the latest updates from ACELYRIN as we execute on our strategy to accelerate the development and delivery of transformative medicines for patients. Register for the webcast on the ‘Events & Presentations’ section of our website. https://lnkd.in/e4dYGq75

It's #HSAwarenessWeek. Brindley Brooks was diagnosed with #HidradenitisSuppurativa (HS) when she was just sixteen. It took her years to find the care she needed. She's since founded HS Connect, an advocacy & support group for those living with this debilitating, chronic illness. Brindley recently sat down with ACELYRIN to share more about her inspirational story. Listen in below and learn more at www.hsconnect.org.

We are pleased to announce that we will present positive proof-of-concept data from an ongoing Phase 1/2 trial of lonigutamab in #thyroideyedisease (TED) at #ENDO2024 in Boston next week. The data will be presented by Dr. Shoaib Ugradar of Thrive Health. Full details below. https://lnkd.in/eKMmi-vu